BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6804290)

  • 1. The monitoring of antigen levels during inactivated poliovirus vaccine production: evaluation of filtration techniques.
    Moynihan M; Petersen I
    Dev Biol Stand; 1981; 50():243-8. PubMed ID: 6804290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV).
    Rezapkin G; Dragunsky E; Chumakov K
    Biologicals; 2005 Mar; 33(1):17-27. PubMed ID: 15713553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. D-antigen determination in polio vaccine production: comparison of gel diffusion and ELISA methods.
    van der Marel P; Hazendonk AG; van Wezel AL
    Dev Biol Stand; 1981; 47():101-8. PubMed ID: 6262140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.
    Rezapkin G; Martin J; Chumakov K
    Biologicals; 2005 Mar; 33(1):29-39. PubMed ID: 15713554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of poliovirus antigen measurements in vitro and in small animals.
    von Seefried A; Bryce E; Campbell JB; Chun JH; Laurence GD; Scollard N; Tsai KS
    Dev Biol Stand; 1981; 47():91-100. PubMed ID: 6262165
    [No Abstract]   [Full Text] [Related]  

  • 6. Killed poliovaccine: an evaluation of safety testing.
    van Steenis G; van Wezel AL
    Dev Biol Stand; 1981; 47():143-50. PubMed ID: 6262145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potency test of killed polio vaccines. Statistical analysis of test on chicken and preliminary results in combination with ELISA D-antigen determinations.
    Larbaigt G; Moulin J; Souvras M; Gibelin N; Beranger G
    Dev Biol Stand; 1981; 47():113-8. PubMed ID: 6262141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA; McInnis J; Albrecht P
    Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of inactivated poliovirus vaccine derived from Sabin strains.
    Simizu B; Abe S; Yamamoto H; Tano Y; Ota Y; Miyazawa M; Horie H; Satoh K; Wakabayashi K
    Biologicals; 2006 Jun; 34(2):151-4. PubMed ID: 16679028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic potency of inactivated poliovirus vaccines.
    Moynihan M; Petersen I
    Dev Biol Stand; 1981; 47():129-33. PubMed ID: 6262143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine.
    Wood DJ; Heath AB; Kersten GF; Hazendonk T; Lantinga M; Beuvery EC
    Biologicals; 1997 Mar; 25(1):59-64. PubMed ID: 9167009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines.
    van Wezel AL; van Herwaarden JA; van de Heuvel-de Rijk EW
    Dev Biol Stand; 1979; 42():65-9. PubMed ID: 223923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct enzyme linked immunosorbent assay (ELISA) for quantification of poliomyelitis virus D-antigen.
    Souvras M; Montagnon B; Fanget B; van Wezel AL; Hazendonk AG
    Dev Biol Stand; 1980; 46():197-202. PubMed ID: 6244997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Present state and developments in the production of inactivated poliomyelitis vaccine.
    van Wezel AL
    Dev Biol Stand; 1981; 47():7-13. PubMed ID: 6262162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine.
    Montagnon BJ; Fanget B; Nicolas AJ
    Dev Biol Stand; 1981; 47():55-64. PubMed ID: 6785126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poliovirus antibody response in serum and nasal secretions following intranasal inoculation with inactivated poliovaccine.
    Ogra PL; Karzon DT
    J Immunol; 1969 Jan; 102(1):15-23. PubMed ID: 4303877
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality control for screening-assays by means of control charts: polio vaccine testing as an example.
    Vogel I
    Dev Biol Stand; 1996; 86():346. PubMed ID: 8785986
    [No Abstract]   [Full Text] [Related]  

  • 18. Presence and quantification of cell substrate DNA in inactivated poliovirus vaccine.
    Crainic R; Horodniceanu F; Barme M
    Dev Biol Stand; 1980; 46():275-9. PubMed ID: 6245003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
    Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
    Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evaluation of a physical method for the quantification of inactivated poliovirus particles and its relationship to D-antigenicity and potency testing in rats.
    Doel TR; Osterhaus AD; van Wezel AL; van Steenis G
    J Biol Stand; 1984 Jan; 12(1):93-9. PubMed ID: 6699027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.